Societal preference values for advanced melanoma health states in the United Kingdom and Australia

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 387-389

  Beusterien, K M ^a   Szabo, S M ^a   Kotapati, S ^b   Mukherjee, J ^b   Hoos, A ^b   Hersey, P ^c   Middleton, M R ^d   Levy, A R ^a,e  

^a ICON PLC   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c Bristol Myers Squibb Co ^*  (Australia)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Melanoma; Preferences; Standard gamble; Utility

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SOCIETY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MELANOMA; MIDDLE AGED;

EID: 68149158282     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605187     Document Type: Article

References (23)

1. Australian Bureau of Statistics (2007a) 2006 Census Table. http://www.abs.gov.au/
2. Australian Bureau of Statistics (2007b) 2006 QuickStats Australia. http://www.censusdata.abs.gov.au/ABSNavigation/prenav/ViewData?subaction= -1&producttype=QuickStats&areacode=0&action=401&collection= Census&textversion=false&breadcrumb=PL&period=2006&javascript= true&navmapdisplayed=true&
3. Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. 9-8-2006
4. Cohen L, de MC, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial. Cancer 91: 1949-1955
5. Crott R (2004) Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 22: 569-580
6. Crott R, Ali F, Burdette-Radoux S (2004) Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 7: 423-432
7. Dale W, Basu A, Elstein A, Meltzer D (2002) Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 28: 102-112
8. Dixon S, Walters SJ, Turner L, Hancock BW (2006) Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 94: 492-498
9. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688
10. England and Wales Census 2007 England and Wales Census, 2001 Data Table. http://www.statistics.gov.uk/census2001/table-list-cas.asp
11. Flanagan W, McIntosh CN, Le PC, Berthelot JM (2006) Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr 4: 13
12. Fu AZ, Kattan MW (2008) Utilities should not be multiplied: evidence from the preference-based scores in the United States. Medical Care 46: 984-990
13. Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21: 821-829
14. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr RF, Weeks JC (2002) Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20: 1311-1318
15. Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF (2001) Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19: 812-823
16. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534
17. National Institute for Clinical Excellence (NICE) (2004) Guide to the Methods of Technology Appraisal. p 20.
18. NICE: London O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627
19. Pickard AS, Wilke CT, Lin HW, Lloyd A (2007) Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25: 365-384
20. Richardson J, Hall J, Salkeld G (1996) The measurement of utility in multiphase health states. Int J Technol Assess Health Care 12: 151-162
21. Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43: 736-749
22. Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5: 1-30
23. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48: Geneva, Switzerland